Lipocine sets sales agent fee up to 3.0%

Lipocine set the Sales Agent’s fee under its existing sales agreement with A.G.P./Alliance Global Partners at up to 3.0%, subject to further adjustment.

Rhea-AI Filing Summary

Lipocine Inc. (LPCN) reported that on September 8, 2026 it agreed with A.G.P./Alliance Global Partners to modify the compensation terms under their existing Sales Agreement dated April 26, 2024. The Sales Agent’s fee on sales made under this agreement will be up to 3.0%, subject to further adjustment by Lipocine and the Sales Agent.

8-K Event Classification

Item 8.01 — Other Events

1 item

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Key Figures

Sales Agent fee: Up to 3.0% Agreement date: April 26, 2024 Fee change agreement date: September 8, 2026

3 metrics

Sales Agent fee Up to 3.0% Fee on sales made under the Sales Agreement with A.G.P./Alliance Global Partners

Agreement date April 26, 2024 Date of the original Sales Agreement with the Sales Agent

Fee change agreement date September 8, 2026 Date Lipocine and the Sales Agent agreed on the up to 3.0% fee

Key Terms

Sales Agreement, Sales Agent, Emerging growth company

3 terms

Sales Agreement financial

"under that certain Sales Agreement dated April 26, 2024 between the Company"

A sales agreement is a written contract that sets out the terms for selling goods, services, or assets, specifying price, delivery, payment schedule and responsibilities of each side. For investors it matters because it creates a predictable stream of revenue or cash obligations, clarifies timing and risk, and can change a company’s value or forecasts much like a signed order turns a customer’s verbal intent into a firm commitment.

Sales Agent financial

"Lipocine Inc. and A.G.P./Alliance Global Partners (the “Sales Agent”) agreed"

A sales agent is an individual or firm authorized to sell a company’s products or services on its behalf, typically paid by commission or fees rather than a fixed salary. For investors, who a company uses to reach customers and how well those agents perform affects revenue growth and profit margins — like hiring local independent sellers to expand into new neighborhoods without building stores — so agent quality and cost matter to future cash flow and valuation.

Emerging growth company regulatory

"Emerging growth company"

An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Lipocine Inc. (LPCN) announce regarding its Sales Agent fee?

Lipocine announced that the Sales Agent’s fee on sales made under its Sales Agreement with A.G.P./Alliance Global Partners will be up to 3.0%, with the exact fee subject to adjustment by mutual agreement of the parties.

When did Lipocine (LPCN) agree to the new Sales Agent fee terms?

Lipocine and A.G.P./Alliance Global Partners agreed to the updated Sales Agent fee terms on September 8, 2026, as disclosed in the company’s current report.

Which agreement is affected by the new 3.0% fee at Lipocine (LPCN)?

The new fee applies to sales made under the Sales Agreement dated April 26, 2024 between Lipocine Inc. and A.G.P./Alliance Global Partners, who serves as the Sales Agent.

Is the 3.0% Sales Agent fee for Lipocine (LPCN) fixed or adjustable?

The Sales Agent’s fee is described as up to 3.0% and is explicitly stated to be subject to adjustment by Lipocine Inc. and A.G.P./Alliance Global Partners.

Who is the Sales Agent under Lipocine’s (LPCN) Sales Agreement?

The Sales Agent under Lipocine’s Sales Agreement is A.G.P./Alliance Global Partners, whose fee on sales under the agreement has been set at up to 3.0%.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/11/2026 - 06:11 AM Accepted by SEC EDGAR 09/11/2026 - 06:10 AM Learn about SEC filing dates

false 0001535955 0001535955 2026-09-08 2026-09-08 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported):

September 8, 2026

 

LIPOCINE INC.

(Exact name of registrant as specified in its charter)

Commission File No. 001-36357

Delaware		99-0370688
(State or other jurisdiction of incorporation)		(IRS Employer Identification Number)

675 Arapeen Drive, Suite 202

Salt Lake City, Utah 84108

(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (801) 994-7383

Former name or former address, if changed since last report: Not Applicable

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.0001 per share		LPCN		The NASDAQ Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR § 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR § 240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01. Other Events.

On September 8, 2026, Lipocine Inc. (the “Company”) and A.G.P./Alliance Global Partners (the “Sales Agent”) agreed that the Sales Agent’s fee on sales made under that certain Sales Agreement dated April 26, 2024 between the Company and the Sales Agent (the “Sales Agreement”) will be up to 3.0%, subject to adjustment by the Company and the Sales Agent.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: September 11, 2026	LIPOCINE INC.
	By:	/s/ Mahesh V. Patel
	Name:	Mahesh V. Patel
	Title:	President and Chief Executive Officer

Filing Exhibits & Attachments

3 documents

Other Documents

• EX-101 XBRL SCHEMA FILE 2.9 KB
• EX-101 XBRL LABEL FILE 33.4 KB
• EX-101 XBRL PRESENTATION FILE 21.8 KB